TR200400402T4 - Kalıcı aminosit hücre türü, bunun üretim ve gen transfer vektörlerinin üretimindeki kullanımı. - Google Patents
Kalıcı aminosit hücre türü, bunun üretim ve gen transfer vektörlerinin üretimindeki kullanımı.Info
- Publication number
- TR200400402T4 TR200400402T4 TR2004/00402T TR200400402T TR200400402T4 TR 200400402 T4 TR200400402 T4 TR 200400402T4 TR 2004/00402 T TR2004/00402 T TR 2004/00402T TR 200400402 T TR200400402 T TR 200400402T TR 200400402 T4 TR200400402 T4 TR 200400402T4
- Authority
- TR
- Turkey
- Prior art keywords
- production
- cell line
- aminocyte
- permanent
- gene transfer
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
- 210000001776 amniocyte Anatomy 0.000 abstract 3
- 230000002068 genetic effect Effects 0.000 abstract 2
- 241000701161 unidentified adenovirus Species 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000012800 visualization Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Manufacturing Of Steel Electrode Plates (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19955558A DE19955558C2 (de) | 1999-11-18 | 1999-11-18 | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200400402T4 true TR200400402T4 (tr) | 2004-03-22 |
Family
ID=7929523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2004/00402T TR200400402T4 (tr) | 1999-11-18 | 2000-11-07 | Kalıcı aminosit hücre türü, bunun üretim ve gen transfer vektörlerinin üretimindeki kullanımı. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1230354B1 (https=) |
| JP (1) | JP4456790B2 (https=) |
| CN (1) | CN100412201C (https=) |
| AT (1) | ATE257512T1 (https=) |
| AU (1) | AU784003B2 (https=) |
| CA (1) | CA2391591C (https=) |
| CZ (1) | CZ300124B6 (https=) |
| DE (2) | DE19955558C2 (https=) |
| DK (1) | DK1230354T3 (https=) |
| ES (1) | ES2211647T3 (https=) |
| HU (1) | HU227440B1 (https=) |
| IL (2) | IL149291A0 (https=) |
| PL (1) | PL205966B1 (https=) |
| PT (1) | PT1230354E (https=) |
| TR (1) | TR200400402T4 (https=) |
| WO (1) | WO2001036615A2 (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1528101A1 (en) * | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| US20070207461A1 (en) | 2004-02-23 | 2007-09-06 | Crucell Holland B.V. | Virus Purification Methods |
| CA2602944C (en) | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| DE102005054628A1 (de) | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
| SI2061803T2 (sl) | 2006-08-28 | 2023-01-31 | Ares Trading S.A. | Postopek za čiščenje proteinov, ki vsebujejo FC |
| US10041049B2 (en) | 2008-11-03 | 2018-08-07 | Janssen Vaccines & Prevention B.V. | Method for the production of adenoviral vectors |
| DE102009003439A1 (de) | 2009-02-05 | 2010-08-26 | Cevec Pharmaceuticals Gmbh | Neue permanente humane Zelllinie |
| CA2777116C (en) | 2009-10-15 | 2020-09-01 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
| JP5393896B2 (ja) | 2009-10-15 | 2014-01-22 | クルセル ホランド ベー ヴェー | アデノウイルス粒子の精製方法 |
| MX2012007936A (es) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
| EP2606128B1 (de) | 2010-08-16 | 2014-09-10 | CEVEC Pharmaceuticals GmbH | Permanente humane amniozyten zellinie zur herstellung von influenzaviren |
| KR101427200B1 (ko) * | 2011-11-24 | 2014-08-07 | 주식회사 바이로메드 | 아데노바이러스 생산 신규 세포주 및 그의 용도 |
| SI2825640T1 (sl) | 2012-03-12 | 2016-08-31 | Crucell Holland B.V. | Šarže rekombinantnega adenovirusa s spremenjenimi konci |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| JP5805908B2 (ja) | 2012-03-22 | 2015-11-10 | クルセル ホランド ベー ヴェー | Ｒｓｖに対するワクチン |
| EP2662451A1 (en) | 2012-05-07 | 2013-11-13 | Stefan Kochanek | Nucleic acid construct and use of the same |
| WO2014060594A1 (en) * | 2012-10-19 | 2014-04-24 | Cevec Pharmaceuticals Gmbh | Production of a hcmv based vaccine in human amniocyte cell lines |
| EP2722337A1 (en) | 2012-10-19 | 2014-04-23 | CEVEC Pharmaceuticals GmbH | Production of a HCMV based vaccine in human amniocyte cell lines |
| KR102236497B1 (ko) | 2013-04-25 | 2021-04-06 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드 |
| CN105408348B (zh) | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| DE112014003136A5 (de) | 2013-07-01 | 2016-04-21 | Charité - Universitätsmedizin Berlin | Immortalisierte humane Chorionzelllinie sowie Verfahren zur Immortalisierung humaner Chorionzellen |
| RS58080B1 (sr) | 2014-11-04 | 2019-02-28 | Janssen Vaccines & Prevention Bv | Terapeutske vakcine protiv hpv16 |
| EP3042952A1 (en) | 2015-01-07 | 2016-07-13 | CEVEC Pharmaceuticals GmbH | O-glycan sialylated recombinant glycoproteins and cell lines for producing the same |
| JP6735288B2 (ja) | 2015-04-14 | 2020-08-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス |
| EA039065B1 (ru) | 2015-07-07 | 2021-11-29 | Янссен Вэксинс Энд Превеншн Б.В. | Вакцина против rsv |
| US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| JP6470872B2 (ja) | 2015-08-20 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 治療用ｈｐｖ１８ワクチン |
| JP7233928B2 (ja) | 2016-04-05 | 2023-03-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Ｒｓｖに対するワクチン |
| IL262108B2 (en) | 2016-04-05 | 2023-04-01 | Janssen Vaccines Prevention B V | Soluble pre-fusion rsv f proteins are stabilized |
| JP7053491B2 (ja) | 2016-05-02 | 2022-04-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 治療用ｈｐｖワクチン組み合わせ |
| CN109154000B (zh) | 2016-05-12 | 2022-07-05 | 扬森疫苗与预防公司 | 有效和平衡的双向启动子 |
| CN109311946A (zh) | 2016-05-30 | 2019-02-05 | 扬森疫苗与预防公司 | 稳定化的融合前rsv f蛋白 |
| RU2745500C2 (ru) | 2016-06-20 | 2021-03-25 | Янссен Вэксинс Энд Превеншн Б.В. | Эффективный и сбалансированный двунаправленный промотор |
| WO2018011196A1 (en) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
| US11034978B2 (en) | 2017-02-09 | 2021-06-15 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
| EP3382014A1 (en) | 2017-03-29 | 2018-10-03 | CEVEC Pharmaceuticals GmbH | Recombinant glycoproteins with reduced antennary fucosylation |
| AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
| WO2019086466A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| WO2019086461A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| WO2019086450A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
| CN111372943B (zh) | 2017-10-31 | 2023-12-05 | 扬森疫苗与预防公司 | 腺病毒及其用途 |
| MX2021005607A (es) | 2018-11-13 | 2021-06-30 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del vrs estabilizadas. |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3736286A1 (en) | 2019-05-09 | 2020-11-11 | Biotest AG | Single chain factor viii molecule |
| JP2022532742A (ja) | 2019-05-15 | 2022-07-19 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置 |
| WO2020229577A1 (en) | 2019-05-15 | 2020-11-19 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
| EP4017521A1 (en) | 2019-09-02 | 2022-06-29 | Biotest AG | Factor viii protein with increased half-life |
| EP3785726A1 (en) | 2019-09-02 | 2021-03-03 | Biotest AG | Factor viii protein with increased half-life |
| US20220372515A1 (en) | 2019-10-03 | 2022-11-24 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| US20230190881A1 (en) | 2020-02-17 | 2023-06-22 | Biotest Ag | Subcutaneous administration of factor viii |
| US20230024133A1 (en) | 2020-07-06 | 2023-01-26 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
| US20230035403A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Method For Determining Responsiveness To Prostate Cancer Treatment |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4229204A1 (en) | 2020-10-15 | 2023-08-23 | F. Hoffmann-La Roche AG | Nucleic acid constructs for simultaneous gene activation |
| CA3197730A1 (en) | 2020-10-15 | 2022-04-21 | F. Hoffman-La Roche Ag | Nucleic acid constructs for va rna transcription |
| TW202323529A (zh) | 2021-10-18 | 2023-06-16 | 美商再生元醫藥公司 | 包括腺病毒相關病毒聚核苷酸的真核細胞 |
| EP4508241A1 (en) | 2022-04-13 | 2025-02-19 | F. Hoffmann-La Roche AG | Method for determining aav genomes |
| CN119256220A (zh) | 2022-05-23 | 2025-01-03 | 豪夫迈·罗氏有限公司 | 用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法 |
| CN119301260A (zh) | 2022-06-03 | 2025-01-10 | 豪夫迈·罗氏有限公司 | 用于生产重组aav颗粒的方法 |
| KR20250036743A (ko) | 2022-07-14 | 2025-03-14 | 에프. 호프만-라 로슈 아게 | 재조합 aav 입자를 생산하는 방법 |
| CA3264505A1 (en) | 2022-09-12 | 2024-03-21 | F. Hoffmann-La Roche Ag | METHOD FOR SEPARING SOLID AND EMPTY VAA PARTICLES |
| AU2024216670A1 (en) | 2023-02-07 | 2025-07-31 | F. Hoffmann-La Roche Ag | Method for the detection of anti-aav particle antibodies |
| AU2024239386A1 (en) | 2023-03-21 | 2025-08-14 | F. Hoffmann-La Roche Ag | Method for the production of recombinant aav particle preparations |
| CN117487761A (zh) * | 2023-09-25 | 2024-02-02 | 南京农业大学 | 表达Cre基因猪骨髓巨噬细胞系的构建方法及其应用 |
| WO2025158316A1 (en) | 2024-01-26 | 2025-07-31 | Janssen Biotech, Inc. | Ovarian neoantigens and use thereof |
| WO2025168663A1 (en) | 2024-02-09 | 2025-08-14 | F. Hoffmann-La Roche Ag | Method for producing recombinant adeno-associated viral particles |
| WO2025252480A1 (en) | 2024-06-07 | 2025-12-11 | F. Hoffmann-La Roche Ag | Method for purifying plasmid dna |
| WO2026022064A1 (en) | 2024-07-22 | 2026-01-29 | F. Hoffmann-La Roche Ag | Novel aav rep orfs and rep polypeptides |
| WO2026037757A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | Modified aav particles |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL160406A0 (en) * | 1995-06-15 | 2004-07-25 | Crucell Holland Bv | A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products |
-
1999
- 1999-11-18 DE DE19955558A patent/DE19955558C2/de not_active Expired - Fee Related
-
2000
- 2000-11-07 PT PT00979539T patent/PT1230354E/pt unknown
- 2000-11-07 WO PCT/EP2000/010992 patent/WO2001036615A2/de not_active Ceased
- 2000-11-07 AT AT00979539T patent/ATE257512T1/de active
- 2000-11-07 EP EP00979539A patent/EP1230354B1/de not_active Expired - Lifetime
- 2000-11-07 CA CA002391591A patent/CA2391591C/en not_active Expired - Lifetime
- 2000-11-07 TR TR2004/00402T patent/TR200400402T4/xx unknown
- 2000-11-07 IL IL14929100A patent/IL149291A0/xx active IP Right Grant
- 2000-11-07 HU HU0203387A patent/HU227440B1/hu not_active IP Right Cessation
- 2000-11-07 CZ CZ20021709A patent/CZ300124B6/cs not_active IP Right Cessation
- 2000-11-07 ES ES00979539T patent/ES2211647T3/es not_active Expired - Lifetime
- 2000-11-07 CN CNB008159017A patent/CN100412201C/zh not_active Expired - Lifetime
- 2000-11-07 DE DE50004995T patent/DE50004995D1/de not_active Expired - Lifetime
- 2000-11-07 DK DK00979539T patent/DK1230354T3/da active
- 2000-11-07 JP JP2001538494A patent/JP4456790B2/ja not_active Expired - Lifetime
- 2000-11-07 PL PL357495A patent/PL205966B1/pl unknown
- 2000-11-07 AU AU16990/01A patent/AU784003B2/en not_active Expired
-
2002
- 2002-04-23 IL IL149291A patent/IL149291A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2211647T3 (es) | 2004-07-16 |
| IL149291A0 (en) | 2002-11-10 |
| IL149291A (en) | 2008-11-26 |
| HUP0203387A2 (hu) | 2002-12-28 |
| DE50004995D1 (de) | 2004-02-12 |
| CN100412201C (zh) | 2008-08-20 |
| PT1230354E (pt) | 2004-04-30 |
| WO2001036615A2 (de) | 2001-05-25 |
| PL205966B1 (pl) | 2010-06-30 |
| DE19955558C2 (de) | 2003-03-20 |
| DK1230354T3 (da) | 2004-03-22 |
| EP1230354A2 (de) | 2002-08-14 |
| EP1230354B1 (de) | 2004-01-07 |
| HUP0203387A3 (en) | 2005-07-28 |
| CZ300124B6 (cs) | 2009-02-18 |
| JP4456790B2 (ja) | 2010-04-28 |
| WO2001036615A3 (de) | 2002-01-10 |
| DE19955558A1 (de) | 2001-06-07 |
| ATE257512T1 (de) | 2004-01-15 |
| CZ20021709A3 (cs) | 2002-08-14 |
| CA2391591C (en) | 2008-12-30 |
| HU227440B1 (en) | 2011-06-28 |
| CN1433476A (zh) | 2003-07-30 |
| PL357495A1 (en) | 2004-07-26 |
| AU784003B2 (en) | 2006-01-12 |
| AU1699001A (en) | 2001-05-30 |
| CA2391591A1 (en) | 2001-05-25 |
| JP2003514526A (ja) | 2003-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200400402T4 (tr) | Kalıcı aminosit hücre türü, bunun üretim ve gen transfer vektörlerinin üretimindeki kullanımı. | |
| Minaguchi et al. | Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene | |
| Lin et al. | Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells | |
| ATE310829T1 (de) | Zelllinien und konstrukte für die herstellung von e1-deletierten adenoviren in abwesenheit von replikationskompetentem adenovirus | |
| WO2004042029A3 (en) | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use | |
| ATE267246T1 (de) | Künstliche chromosomen, die die genetische information für die bildung von rekombinantem rna-virus enthalten | |
| FI951138A0 (fi) | Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa | |
| CA2263725A1 (en) | Immortalized cell lines for virus growth | |
| JP2003525623A5 (https=) | ||
| MXPA01010392A (es) | Produccion de vacunas de virus con arn de hebra negativa atenuados a partir de secuencias de nucleotidos clonadas. | |
| WO2002048329A3 (en) | Membrane derived caspase-3, compositions comprising the same and methods of use therefor | |
| CA2278808A1 (en) | Methods for cultivating cells and propagating viruses | |
| DE69738903D1 (de) | Allel-abbau | |
| ATE342998T1 (de) | Replikation -defektive baculoviren expressionssystem | |
| Murty et al. | Deletion mapping identifies loss of heterozygosity at 5p15. 1-15.2, 5q11 and 5q34-35 in human male germ cell tumors. | |
| PT1071805E (pt) | Vectores adenovirais para tratamento de doença | |
| AU4903099A (en) | Targeted integration into chromosomes using retroviral vectors | |
| Khier et al. | Molecular cloning and characterization of the mouse histone deacetylase 1 gene: integration of a retrovirus in 129SV mice | |
| Xia et al. | Construction of recombinant adenoviral vector carrying human tissue inhibitor of metalloproteinase-1 gene and its expression in vitro | |
| ATE397065T1 (de) | Regulatorische konstrukte, die das intron 3 des prostat-spezifischen membranatigen-gens enthalten | |
| Asch et al. | Epigenetics and breast cancer | |
| WO2001002540A3 (en) | Adenoviral vectors for treating disease | |
| AU7794700A (en) | Recombinant adenoviruses preparation and adenovirus banks | |
| DE59912375D1 (de) | Retrovirale Gentransfervektoren | |
| FI971377A7 (fi) | Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geen iä: itsemurha- ja immuunistimuloiva geeni |